Kisspeptin-10

Reproduction runs on a relay. The hypothalamus releases GnRH in pulses, the pituitary answers with LH and FSH, and those two hormones tell the testes or ovaries to make testosterone or estradiol and to mature sperm or eggs. Kisspeptin sits one step above GnRH. Kisspeptin neurons in the hypothalamus, many of which also make a partner signal called neurokinin B, set the pace of those GnRH pulses.

The 2003 mouse work showed how specific that job is. Mice without the receptor still had normal amounts of GnRH stored in the hypothalamus, and they still responded when GnRH or gonadotropins were given. The machinery downstream, pituitary and gonads, worked. What was missing was the signal to start it.

Kisspeptin comes in several lengths. Kisspeptin-54 is the major form circulating in human blood, and kisspeptin-10 is the minimal sequence that keeps full activity at the receptor. In men, kisspeptin-54 has a half-life in blood of about 28 minutes, and human studies have used both single injections and infusions.

Reviews also describe kisspeptin acting on sexual behavior and attraction, the placenta and bone. Its neighbor, neurokinin B, drives menopausal hot flashes, and a drug that blocks its receptor, fezolinetant, is now approved for them. That approval shows how ready this small corner of the brain has become for medicine.^8751413

The first study of kisspeptin-10 in people came from Edinburgh in 2011. Given as a single injection into a vein, it caused a rapid, dose-dependent rise in LH in healthy men, roughly tripling it within 30 minutes at the most effective dose. A higher dose produced a smaller response, an early hint that more is not always better with this signal.

Longer infusions showed what happens downstream. Over 22.5 hours, LH rose about fourfold and testosterone climbed from 16.6 to 24.0 nmol/L. A gentler infusion revealed the mechanism more clearly, raising LH pulse frequency from 0.7 to 1.0 pulses an hour and making each burst larger. That is consistent with kisspeptin-10 speeding up the body’s own GnRH rhythm, which cannot be measured directly in people.

A London group had already shown the same direction with the longer kisspeptin-54. In a 2005 double-blind crossover study of 6 men, a 90-minute infusion raised LH, FSH and testosterone compared with saline.

The practical question is whether the effect lasts. A 2026 Imperial College study of 15 healthy men, split across three experiments, gave kisspeptin-10 under the skin. In four men, five days of continuous infusion left LH and FSH no higher than placebo, although testosterone stayed raised. In seven others, intermittent infusions, running for part of each day, kept gonadotropins up across 12 days, and the receptor still responded at the end.¹³²

Low testosterone is common in men with type 2 diabetes and severe obesity, and it is tempting to assume the testes have simply worn out. In 2010, the Edinburgh team proposed another explanation. Evidence pointed to the hypothalamus releasing less GnRH in these men, and they hypothesized that falling kisspeptin is the common pathway linking high blood sugar, inflammation, leptin and estrogen feedback to low testosterone.

In 2013 they tested the idea in a proof-of-concept study. Five men with type 2 diabetes and low testosterone, with an average BMI of about 40, were given kisspeptin-10. Their LH rose about as much as it did in seven healthy men. During an 11-hour infusion in four of them, LH pulse frequency increased and testosterone rose from 8.5 to 11.4 nmol/L.

In these five men, the pituitary and testes could still answer when called. That is consistent with a quiet signal upstream, though it does not prove missing kisspeptin is the cause. Picture a factory with a working production line and a phone that has stopped ringing. One way to read it is that some metabolic low testosterone is a message problem, and it explains why weight, blood sugar and inflammation keep turning up in a hormone story.

This is still a hypothesis built on very small studies, and it does not make kisspeptin a therapy for diabetes-related low testosterone. It does suggest two practical habits. Measure LH alongside testosterone, and count metabolic health as part of the hormone conversation instead of a separate topic.¹²¹³

Hypothalamic amenorrhea is the loss of periods because the brain stops sending its signal, while the ovaries remain healthy. In 2010, a London team gave kisspeptin-54 to women with the condition. Frequent injections lost their effect quickly, with the FSH response nearly gone by the second day.

Spacing made the difference. A less frequent schedule caused only partial desensitization, and after 8 weeks those women had significantly higher reproductive hormones than women given saline. No adverse effects were seen. The lesson runs through all kisspeptin work. The axis listens to rhythm, and constant exposure tunes it out.

The most clinical use so far is in IVF. In 2014, 53 women undergoing IVF received a single injection of kisspeptin-54 to trigger the final maturation of their eggs. Embryos were transferred in 92 percent, and 23 percent had a clinical pregnancy. Because kisspeptin works through the body’s own GnRH, reviewers describe it as a potentially safer, more physiological trigger for this step.

These studies used kisspeptin-54, the longer form. Their results are a guide to what the kisspeptin system can do, and they should not be assumed to transfer automatically to kisspeptin-10.⁴¹⁴⁸

Kisspeptin’s reach goes beyond hormone levels. In a 2022 trial at Imperial College London, 32 premenopausal women with hypoactive sexual desire disorder received a 75-minute infusion of kisspeptin-54 on one day and placebo on another, while their brains were scanned as they watched erotic videos and looked at faces. Kisspeptin shifted activity in regions tied to sexual and attraction processing.

Some of those changes tracked with how the women felt. Kisspeptin’s boost to hippocampal activity during erotic videos was larger in women with more baseline distress about their sexual function, and its effect in a region called the posterior cingulate cortex correlated with lower sexual aversion. It was well tolerated, with no reported adverse effects.

A matching 2023 trial in 32 men with low desire found kisspeptin modulated the brain’s sexual-processing network, increased penile tumescence during sexual videos by up to 56 percent more than placebo, and raised happiness about sex. The authors suggested kisspeptin could become the first drug for low desire in men.

These were single infusions in a scanner, and brain signals are a long way from months of daily life. They do suggest that the hormone at the top of the reproductive chain also speaks to the parts of the brain that decide whether sex feels appealing.¹⁵¹⁶

Lay the human record side by side and it is a set of careful, small physiology studies. Most enrolled between 5 and 53 people, ran for hours to weeks, and measured hormones or brain signals. Together they show that kisspeptin can drive the human reproductive axis on demand. They do not yet show better fertility, better sex lives or symptom relief from kisspeptin-10 itself.

The question many men bring to kisspeptin is whether it can protect fertility on testosterone therapy, which suppresses LH, FSH and sperm production. A 2026 narrative review of peptide strategies for that problem found that kisspeptin approaches may support the body’s own hormone signaling, but that direct evidence of restored sperm production or fertility after testosterone suppression remains limited.

Much of the human work also comes from a small number of research groups, mainly in London and Edinburgh. That gives the field consistent methods, and it is also a reason to want independent replication before any of these findings are taken as settled.^1131429

In short human studies, kisspeptin has been well tolerated. The 8-week kisspeptin-54 study in women observed no adverse effects, and the brain imaging trial in women reported none. The 2026 kisspeptin-10 study in men ran for 12 days. None of these tells us what happens over months or years.

The main known limit is tolerance. Constant or too-frequent exposure blunts the response. Frequent kisspeptin-54 injections produced complete tolerance in women, and five days of continuous kisspeptin-10 left gonadotropins no higher than placebo in men. A poorly designed schedule can leave it doing nothing for LH and FSH.

Product quality is the other issue. FDA has said compounded kisspeptin-10 may pose a risk of immunogenicity, meaning the immune system could react to it, and may contain peptide-related impurities that are hard to characterize. It also notes no, or only limited, safety information for the proposed routes.

Because kisspeptin raises sex hormones, people with hormone-sensitive cancers, anyone pregnant or trying to conceive, and anyone already on testosterone or another hormonal medicine should talk with a clinician first.⁴¹⁵²¹⁸

Kisspeptin research is really a study of a relay, and four blood tests show which runner has slowed. LH is the pituitary’s message to the gonads. In men, a low or normal LH alongside low testosterone points up the chain, toward the hypothalamus or pituitary. A high LH with low testosterone points down, toward the testes.

FSH is LH’s partner, driving sperm production in men and follicle growth in women. Total testosterone is the main output of the axis in men. Estradiol tracks the ovarian cycle in women and, in men, estrogen made mostly from androgens, which also feeds back on the brain.

Measured together and repeated, these four turn a vague complaint into a map. That is how Vitals Vault approaches hormone questions. A blood panel at Quest Diagnostics comes first, a licensed clinician reads it alongside your history, and a retest shows which way the numbers are moving.⁸¹³

Kisspeptin-10 is not FDA-approved for any use. On September 29, 2023, FDA placed it in category 2 of bulk substances nominated for 503A compounding, citing immunogenicity risk, impurity concerns and limited safety information. It was not among the six peptides covered by FDA’s October 29, 2026 enforcement discretion, so that policy does not open a compounding route for it.

Sport has its own rule. The World Anti-Doping Agency’s 2026 Prohibited List names kisspeptin and its agonists under S2.2.1, testosterone-stimulating peptides prohibited in males, in and out of competition.¹⁸¹⁷¹⁹

Kisspeptin is the signal at the very top of the reproductive chain, found in a hunt for melanoma genes and confirmed by families whose puberty never started. Kisspeptin-10, its shortest active piece, reliably raises LH and testosterone in men in small studies, and related work with the longer form points to roles in fertility treatment and in how the brain handles desire.

If low testosterone or irregular cycles are your question, the useful first step is to find out where the chain has gone quiet. LH and FSH read next to properly timed testosterone or estradiol, and your history, help a clinician tell whether the message or the gland looks like the problem, sometimes with more testing to settle it.⁵¹⁸